Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| KMDA | 6-K | bullish | 6/10 | Kamada announced a three-year agreement to supply normal source plasma from its Texas collection centers to a leading bi | Jul 20, 2026 |
| CANF | 6-K | bullish | 5/10 | Can-Fite announced that positive Phase 2a data for Namodenoson in advanced pancreatic cancer was accepted for poster pre | Jul 20, 2026 |
| ONCY | 8-K | bullish | 6/10 | Oncolytics Biotech announced FDA Fast Track Designation for pelareorep in combination with a checkpoint inhibitor for se | Jul 20, 2026 |
| AAPG | 6-K | neutral | 4/10 | Ascentage Pharma filed a 6-K announcing a proposed at-the-market (ATM) offering of up to $200 million in ADSs via an aut | Jul 20, 2026 |
| MOLN | 6-K | neutral | 3/10 | Molecular Partners announced dosing of first patients in the Phase 2 TACTIC trial of MP0317 for first-line cholangiocarc | Jul 20, 2026 |
| FDMT | 8-K | bullish | 7/10 | 4D Molecular Therapeutics reported positive 2-year data from the PRISM Phase 2b trial of 4D-150 in wet AMD, showing 78% | Jul 20, 2026 |
| OPTH | 6-K | bullish | 5/10 | CEO Dane Stevens purchased 18,700 common shares of Optimi Health Corp. on July 15-16, 2026, through a controlled entity, | Jul 20, 2026 |
| ENLV | 6-K | bullish | 7/10 | Enlivex disclosed a quarterly treasury update as of July 18, 2026, reporting net asset value per ordinary share of $66.1 | Jul 20, 2026 |
| AVXL | 8-K | neutral | 3/10 | Anavex Life Sciences submitted a compliance plan to Nasdaq on July 20, 2026, to address its late filing of the March 31, | Jul 20, 2026 |
| KLRS | 8-K | neutral | 3/10 | Kalaris Therapeutics appointed Liisa Bayko as CFO and Treasurer, effective July 20, 2026, with a $475K base salary, 40% | Jul 20, 2026 |
| OKYO | 6-K, 20-F | neutral | 4/10 | OKYO Pharma filed its annual report (20-F) for FY2026 ended March 31, 2026, alongside a 6-K press release highlighting a | Jul 20, 2026 |
| ARMP | 8-K | bullish | 5/10 | Armata Pharmaceuticals announced clinical, regulatory, and manufacturing progress for its lead candidate AP-SA02, includ | Jul 20, 2026 |
| SCTX | S-1/A | neutral | 5/10 | Scribe Therapeutics, a clinical-stage CRISPR biotech engineering in vivo genetic medicines for cardiovascular disease, f | Jul 20, 2026 |
| RGNX | 8-K | bearish | 6/10 | REGENXBIO priced a public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warr | Jul 20, 2026 |
| DYN | 8-K | bullish | 7/10 | Dyne Therapeutics announced FDA acceptance of its BLA for z-rostudirsen (DYNE-251) for Duchenne muscular dystrophy amena | Jul 20, 2026 |
| IMRN | 6-K | neutral | 3/10 | Immuron Ltd filed a 6-K containing an investor presentation from CEO Steven Lydeamore at a Kalkine Media Webinar. The pr | Jul 20, 2026 |
| MLTX | CLUSTER | bearish | 4/10 | MoonLake Immunotherapeutics (MLTX) CEO and CSO sold a combined $1.69M of shares in open-market transactions over the pas | Jul 20, 2026 |
| PHAT | PRESS-RELEASE | neutral | 1/10 | Phathom Pharmaceuticals announced it will report its Q2 2026 results on July 30, 2026. | Jul 20, 2026 |
| EIKN | PRESS-RELEASE | neutral | 3/10 | Eikon Therapeutics announced that seven abstracts covering its pipeline (EIK1001, EIK1003, EIK1004, EIK1005) have been a | Jul 20, 2026 |
| OKYO | PRESS-RELEASE | bullish | 5/10 | OKYO Pharma filed its annual report and provided a corporate update highlighting a $22M capital raise, $20.6M cash posit | Jul 20, 2026 |
| HROW | PRESS-RELEASE | neutral | 5/10 | Harrow presented three studies at ASRS 2026 supporting IHEEZO and BYOOVIZ, including interim randomized data suggesting | Jul 20, 2026 |
| INDP | EFFECT | bearish | 6/10 | Indaptus Therapeutics' S-3 registration statement (File No. 333-297088) became effective on July 17, 2026, enabling sell | Jul 20, 2026 |
| MPLT | CLUSTER | neutral | 4/10 | A cluster of open-market share sales by five top executives at MapLight Therapeutics (MPLT) occurred over a two-week win | Jul 20, 2026 |
| AGEN | S-3 | bearish | 5/10 | Agenus filed an S-3 registration statement to register 2,133,333 shares of common stock for resale by Zynext Ventures US | Jul 20, 2026 |
| DCOY | EFFECT | neutral | 4/10 | The SEC declared effective a registration statement (File No. 333-297381) for Decoy Therapeutics Inc. as of July 17, 202 | Jul 20, 2026 |
| SUPN | COURT-RULING | bearish | 6/10 | The Delaware Superior Court granted summary judgment to US WorldMeds in a breach-of-contract suit against Supernus, ruli | Jul 19, 2026 |
| SPRY | COURT-RULING | neutral | 3/10 | The court transferred ARS Pharmaceuticals' antitrust lawsuit against AptarGroup to the Southern District of New York und | Jul 19, 2026 |
| FDMT | PRESS-RELEASE | bullish | 6/10 | 4D Molecular Therapeutics announced positive 2-year data from the PRISM Phase 2b trial of 4D-150 in wet AMD, showing 78% | Jul 18, 2026 |
| GLUE | CLUSTER | neutral | 2/10 | President & CEO Markus Warmuth and COO Jennifer Champoux sold a combined $322K in open-market sales over two days, with | Jul 18, 2026 |
| CGON | CLUSTER | neutral | 2/10 | Two CG Oncology directors sold a combined $1.89M in stock over a 7-day window, with the bulk ($1.82M) sold by director J | Jul 18, 2026 |